Dolutegravir 50mg
Showing 1 - 25 of >10,000
AIDS Trial (Dolutegravir 50 MG plus lamivudine 300 MG; Dolutegravir/lamivudine (50 MG/300 MG))
Not yet recruiting
- Acquired Immunodeficiency Syndrome
- Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
- (no location specified)
Aug 6, 2022
HIV-1-infection Trial in Liège (Dolutegravir 50 MG)
Recruiting
- HIV-1-infection
- Dolutegravir 50 MG
-
Liège, BelgiumLiège university hospital
Apr 27, 2022
Severely Immunocompromised HIV Patients Trial in Salvador, Rio de Janeiro, Porto Alegre (Dolutegravir 50 mg, Efavirenz-based
Completed
- Severely Immunocompromised HIV Patients
- Dolutegravir 50 mg
- Efavirenz-based regimens
-
Salvador, Bahia, Brazil
- +2 more
Mar 15, 2022
Tuberculosis, Hiv Trial in Durban (Dolutegravir 50 MG)
Recruiting
- Tuberculosis
- Hiv
- Dolutegravir 50 MG
-
Durban, KwaZulu-Natal, South AfricaKing Edward VIII Hospital
May 18, 2022
HIV Trial in Spain (Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato])
Active, not recruiting
- HIV Infections
- Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
-
Vigo, Pontevedra, Spain
- +16 more
Jun 20, 2022
HIV/TB Coinfection Trial in Thailand (DTG 50 mg OD with food, DTG 50 mg BID)
Recruiting
- HIV/TB Coinfection
- DTG 50 mg OD with food
- DTG 50 mg BID
-
Chiang Rai, Chiangrai, Thailand
- +9 more
Mar 22, 2022
HIV-associated Tuberculosis Trial in South Africa, Thailand (Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC,
Not yet recruiting
- HIV-associated Tuberculosis
- Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
- +3 more
-
Mowbray, Cape Town, Western Cape, South Africa
- +3 more
Nov 18, 2022
HIV/AIDS, Tuberculosis, Pulmonary Trial in Durban (Biktarvy®, TLD- fixed-drug combination single tablet)
Recruiting
- HIV/AIDS
- Tuberculosis, Pulmonary
- Biktarvy®
- TLD- fixed-drug combination single tablet
-
Durban, KwaZulu-Natal, South AfricaCAPRISA Springfield Clinical Research Site
Mar 14, 2022
HIV-1-infection Trial (Cabotegravir/Rilpivirine, Antiretroviral)
Recruiting
- HIV-1-infection
-
Kisumu, Kenya
- +6 more
Feb 1, 2023
HIV-1 Infection Trial in Yaoundé (Dolutegravir 50 mg, Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg, Efavirenz 400
Completed
- HIV-1 Infection
- Dolutegravir 50 mg
- +2 more
-
Yaoundé, Cameroon
- +2 more
Aug 26, 2021
HIV, Acute HIV Infection Trial in Chapel Hill, Durham (Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg)
Completed
- HIV
- Acute HIV Infection
- Dolutegravir 50 mg
- +2 more
-
Chapel Hill, North Carolina
- +1 more
Oct 22, 2021
REal-Life Cohort With DOlutegravir + LAmivudina
Recruiting
- HIV-1-infection
- Dolutegravir 50 MG
- Lamivudine 300 MG
-
Madrid, SpainAlfonso Cabello
Apr 5, 2021
Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis Trial in Cape Town (BTZ-043, Rifafour e-275®, Probe Drug
Completed
- Pulmonary Tuberculoses
- Other Specified Pulmonary Tuberculosis
- BTZ-043
- +3 more
-
Cape Town, South Africa
- +1 more
Aug 9, 2022
HIV, Fatty Liver Disease Trial in Madrid (Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil
Recruiting
- HIV Infections
- Fatty Liver Disease
- Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
- +2 more
-
Madrid, Spain
- +3 more
Jun 13, 2023
HIV/AIDS, ESRD Trial in Indianapolis (JULUCA 50Mg-25Mg Tablet)
Recruiting
- HIV/AIDS
- ESRD
- JULUCA 50Mg-25Mg Tablet
-
Indianapolis, IndianaSamir Gupta
Dec 1, 2021
Medication Adherence, HIV Trial in Pittsburgh (dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet
Completed
- Medication Adherence
- HIV
- dolutegravir oral tablet 50mg
- +3 more
-
Pittsburgh, PennsylvaniaHIV/AIDS Clinical Research Unit / University of Pittsburgh
Mar 2, 2022
HIV Trial in Worldwide (Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs)
Recruiting
- HIV Infections
- Darunavir (DRV) 800 milligram (MG) Oral Tablet
- +6 more
-
Chennai, India
- +6 more
Aug 30, 2021
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases Trial in Augusta (Dolutegravir 50 MG, Antiretroviral/Anti
Unknown status
- HIV-1-infection
- +7 more
- Dolutegravir 50 MG
- Antiretroviral/Anti HIV
-
Augusta, GeorgiaAugusta University
Jan 11, 2021
Hiv, HIV, HIV Lipodystrophy Trial in Denmark (Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO],
Recruiting
- Hiv
- +6 more
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
-
Aalborg, Denmark
- +4 more
May 21, 2021
Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and
Completed
- HIV-1-infection
- Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG
- (no location specified)
Aug 20, 2020
Hiv, HIV-1-infection Trial in Buenos Aires (Lamivudine 300 MG, Emtricitabine / Tenofovir Disoproxil Pill)
Active, not recruiting
- Hiv
- HIV-1-infection
- Lamivudine 300 MG
- Emtricitabine / Tenofovir Disoproxil Pill
-
Buenos Aires, ArgentinaFundacion IDEAA
Jan 2, 2023
HIV-1-infection Trial in Montréal (abacavir, dolutegravir and lamivudine dispersible tablets, Triumeq Dispersible Tablets 5 mg
Completed
- HIV-1-infection
- abacavir, dolutegravir and lamivudine dispersible tablets
- Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
-
Montréal, Quebec, CanadaAltasciences
Mar 10, 2022
HIV/AIDS, HIV-1-infection, Osteopenia Trial in United States (Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE
Withdrawn
- HIV/AIDS
- +2 more
- Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
- Current tenofovir alafenamide (TAF)-containing ART regimen
-
Birmingham, Alabama
- +9 more
Mar 10, 2021
HIV-1-infection, Solid Organ Transplant Trial in Barcelona (Lamivudine 300 MG, Abacavir 600 MG, Dolutegravir 50 mg)
Unknown status
- HIV-1-infection
- Solid Organ Transplant
- Lamivudine 300 MG
- +4 more
-
Barcelona, SpainHospital Clínico y provincial de Barcelona
Feb 4, 2020